1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
61485EBA50E099E4000258B9000295277
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/db-medical-affairs-product-launch-in-oncology-roles-collaboration-evolution?opendocument
18
19opendocument
203.235.145.252
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25DB




» Products & Services » » Medical Affairs » Launch Optimization

Medical Affairs Product Launch in Oncology: Roles, Collaboration, and Evolution

ID: 5829


Features:

7 Info Graphics

15 Data Graphics

300+ Metrics

18 Narratives


Pages/Slides: 31


Published: 2024


Delivery Format: Online PDF Document


 

License Options:


Buy Now

 


  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • SPECIAL OFFER
Non-members: Click here to review a complimentary excerpt from “Medical Affairs Product Launch in Oncology: Roles, Collaboration, and Evolution”

STUDY OVERVIEW

In the fiercely competitive field of oncology, Medical Affairs teams play a pivotal role in driving successful product launches. Their ability to adapt, lead, and foster cross-functional collaboration is essential to aligning cutting-edge clinical evidence with the ever-evolving market demands.


Best Practices, LLC undertook this benchmarking research to investigate how the role of Medical Affairs is evolving in oncology product launches, focusing on leadership, cross-functional collaboration, and adaptation to new developments. The study provides insights into how Medical Affairs teams are fostering innovation and aligning internal and external stakeholders to ensure new therapies are positioned for optimal impact.

KEY TOPICS

  • Medical Leadership Roles and Launch Activity Effectiveness in Oncology
  • Ensuring Cross-functional Alignment and Collaboration in Oncology Launches
  • Adopting to Ongoing Changes in Medical Landscape

KEY METRICS

  • Medical Affairs’ leadership role in oncology launches
  • Optimizing Medical Affairs launch activities in oncology
  • Improvement areas for Medical Affairs around oncology launches
  • Medical Affairs’ internal collaboration for oncology launch success
  • Medical Affairs’ cross-functional team role in oncology product launches

SAMPLE KEY FINDINGS

  • Launch Activity Effectiveness: In the oncology segment, Medical Affairs plays a critical role in product launches, particularly in education and support functions. Educational activities are led by 86% of teams, with 78% rating them as effective. Organizational support is led by 53%, with 72% finding it effective. In contrast, Communication and Data Dissemination activities see less leadership (30%), with 67% rating them effective. Research is led by 52%, with 71% finding it effective. These insights highlight the need for stronger leadership in communication efforts to optimize launch success in oncology.

METHODOLOGY

This benchmarking study engaged 27 Medical leaders from 20 leading life sciences organizations. The study insights are drawn primarily from Medical Directors and upper management executives, representing nearly 80% of the benchmark class.

Industries Profiled:
Pharmaceutical; Health Care; Biotech; Chemical; Consulting; Communications; Consumer Products; Medical Device; Science


Companies Profiled:
AstraZeneca; Boehringer Ingelheim; Eisai; EMD Serono; Eurofarma; Genentech; GRAIL; Helsinn; Ipsen; Karyopharm Therapeutics; MEDiSTRAVA; Merck KGaA; NexGen Healthcare Communications; Novartis; Pfizer; Pixacore; Sandoz; Takeda Pharmaceuticals; Terumo BCT: Terumo Blood and Cell Technologies; Thermo Fisher Scientific

If you purchase Best Practice Database document(s), you will have 30 days from the date of purchase to apply some or all of the cost of the document(s) toward the cost of a Full Access Individual, Pharma, Group or University Membership. Write us at DatabaseTeam@bestpracticesllc.com or call David Guinn at 919-767-9179 if you have any questions.